[关键词]卵巢肿瘤；程序性细胞死亡受体1;安罗替尼；治疗结果;影响因素分析[中图分类号] R737.31；R392.1 [文献标志码]A [文章编号] 2096-5532(2025)03-0406-05doi：10.11712/jms.2096-5532.2025.61.091 [开放科学(资源服务)标识码(OSID)][网络出版] https：//link.cnki.net/urlid/37.1517.R.20250724.1407.001; 2025-07-2417：18：18

    Influencingfactorsfortreatmentoutcomeofanlotinibcombined withPD-1inibitors inadvanced epithelialovariancancerandtheir predictive eficacyGETan，SHEN Jian，ZHAORong(Pharmacy Departmentof Ruijin Hospital，Shanghai Jiaotong University School of Medicine，Shanghai 20o025，China)

    [Abstract]ObjectiveTo investigate thefactors influencing the clinicaloutcomeof anlotinib combined with programmed death-1(PD-1)inibitors treatingadvancedepithelialovariancancer(EOC)andtheirpredictiveeficacy.MethodsWedivided 157 patientswithadvancedEOCtreatedwithanlotinibcombinedwithPD-1inhibitorsinourhospitalfromAugust202OtoAugust 2023intogoodoutcome groupand pooroutcomegroup.Basedonthepatients’clinicaland biochemical data，thefactorsaffecting clinicaloutcome wereanalyzed，andtheirpredictiveeficacywasaessed.ResultsHighgradeserouscarcioma，aphsicalsta tus(PS) score of 2 points ......